Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445261 | 0.78 | MAOA (0.42) | LMNAPOLB | |
| SCHEMBL27289966 | 0.73 | LMNA (0.54) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL6369619 | 0.72 | LMNA (0.41) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL8497505 | 0.72 | MAOA (0.42) | — | |
| SCHEMBL26957474 | 0.72 | CYP3A4 (0.36) | — | |
| SCHEMBL18563787 | 0.68 | CYP2C19 (0.37) | LMNAPOLBMAPTTP53 | |
| SCHEMBL256350 | 0.68 | CYP3A4 (0.37) | — | |
| SCHEMBL13654392 | 0.66 | PIK3CA (0.38) | — | |
| SCHEMBL22788529 | 0.65 | DRD2 (0.42) | LMNAPOLBMAPTTP53HSP90AB1 | |
| SCHEMBL21499251 | 0.65 | LMNA (0.44) | LMNAPOLBMAPTTP53HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | WNT1, WNT3A, CTNNB1 | LMNA 2673/4885POLB 3111/4885MAPT 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.